Our first mandate report
We are happy to share with you the report from our first mandate as an NCE-KM program.
Funded in 2014, CellCAN has been renewed for a second funding cycle from 2018 to 2021.
More than ever, our mission to mobilize knowledge to to improve the quality, safety and feasibility of cell and gene therapy in Canada through optimal manufacturing practices is crucial.
Discover the impact we already had and what is coming in the next years.